PMID- 25071010
OWN - NLM
STAT- MEDLINE
DCOM- 20150603
LR  - 20220321
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 5
IP  - 16
DP  - 2014 Aug 30
TI  - Transcriptional regulation of the p73 gene by Nrf-2 and promoter CpG methylation 
      in human breast cancer.
PG  - 6909-22
AB  - To understand the transcriptional regulation of p73 by promoter methylation and 
      Nrf-2 in breast carcinogenesis, ChIP assay indicated that Nrf-2 can bind to both 
      promoters and can activate the transcription of TAp73 and DeltaNp73 in MCF-7 cell 
      line, knockdown of Nrf-2 gene resulted in an abrogation of TAp73 and DeltaNp73 
      expression in the cells transfected with sh-Nrf-2 as well as Nrf-2 knock out 
      mouse model. However, we found Nrf-2 induced DeltaNp73 expression was abolished with 
      5-aza-dC treatment, thus lead to a down-regulated DeltaNp73 and an up-regulated TAp73 
      expression in breast cancer cells lines. Consistent with this model, we detected 
      decreased TAp73 and increased DeltaNp73 expression in breast cancer tissue, along 
      with increased TAp73 but decreased DeltaNp73 expression in corresponding surrounding 
      noncancerous tissues (NCTs) in a breast cancer tissue assay. A significant 
      inverse correlation was found between TAp73 and DeltaNp73 expression in the above 
      tissue-array (P = 0.047) and validated in another set consisting of 128 breast 
      cancer tumor tissue (P = 0.034). Taken together, our findings suggest that Nrf-2 
      and promoter methylation cooperatively govern the transcriptional regulation of 
      p73, and unbalanced expression of TAp73 and DeltaNp73 expression plays a critical 
      role in breast cancer development.
FAU - Lai, Jing
AU  - Lai J
AD  - Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern 
      Medical University, Guangzhou, China; These authors contributed equally to this 
      work.
FAU - Nie, Weiwei
AU  - Nie W
AD  - Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern 
      Medical University, Guangzhou, China; These authors contributed equally to this 
      work.
FAU - Zhang, Wenwen
AU  - Zhang W
AD  - Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing 
      University, Nanjing, China; These authors contributed equally to this work.
FAU - Wang, Yucai
AU  - Wang Y
AD  - Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
FAU - Xie, Ruilian
AU  - Xie R
AD  - Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern 
      Medical University, Guangzhou, China.
FAU - Wang, Yanru
AU  - Wang Y
AD  - Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern 
      Medical University, Guangzhou, China.
FAU - Gu, Jun
AU  - Gu J
AD  - Department of General Surgery, Jinling Hospital, Medical School of Nanjing 
      University, Nanjing, China.
FAU - Xu, Jing
AU  - Xu J
AD  - Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing 
      University, Nanjing, China.
FAU - Song, Wei
AU  - Song W
AD  - Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern 
      Medical University, Guangzhou, China.
FAU - Yang, Fang
AU  - Yang F
AD  - Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing 
      University, Nanjing, China.
FAU - Huang, Guichun
AU  - Huang G
AD  - Department of Medical Oncology, Jinling Hospital, Medical School of Nanjing 
      University, Nanjing, China.
FAU - Cao, Peng
AU  - Cao P
AD  - Laboratory of Cellular and Molecular Biology, Jiangsu Province Institute of 
      Chinese Medicine, Nanjing, China.
FAU - Guan, Xiaoxiang
AU  - Guan X
AD  - Department of Medical Oncology, Jinling Hospital, School of Medicine, Southern 
      Medical University, Guangzhou, China; Department of Medical Oncology, Jinling 
      Hospital, Medical School of Nanjing University, Nanjing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (TP73 protein, human)
RN  - 0 (Trp73 protein, mouse)
RN  - 0 (Tumor Protein p73)
RN  - 0 (Tumor Suppressor Proteins)
RN  - 0 (delta Np73 protein, human)
SB  - IM
MH  - Animals
MH  - Apoptosis/genetics
MH  - Breast Neoplasms/*genetics/pathology
MH  - Cell Proliferation/genetics
MH  - *CpG Islands
MH  - *DNA Methylation
MH  - DNA-Binding Proteins/*genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, Tumor Suppressor
MH  - Humans
MH  - MCF-7 Cells
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - NF-E2-Related Factor 2/*genetics
MH  - Nuclear Proteins/*genetics
MH  - Promoter Regions, Genetic
MH  - Transfection
MH  - Tumor Protein p73
MH  - Tumor Suppressor Proteins/*genetics
PMC - PMC4196172
COIS- Conflict of Interest The authors declare that they have no competing interests.
EDAT- 2014/07/30 06:00
MHDA- 2015/06/04 06:00
PMCR- 2014/08/01
CRDT- 2014/07/30 06:00
PHST- 2014/07/30 06:00 [entrez]
PHST- 2014/07/30 06:00 [pubmed]
PHST- 2015/06/04 06:00 [medline]
PHST- 2014/08/01 00:00 [pmc-release]
AID - 2230 [pii]
AID - 10.18632/oncotarget.2230 [doi]
PST - ppublish
SO  - Oncotarget. 2014 Aug 30;5(16):6909-22. doi: 10.18632/oncotarget.2230.